Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-05-04
2000-08-01
Bernhardt, Emily
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544354, A61K 31498, C07D24144
Patent
active
060967447
ABSTRACT:
A novel series of substituted quinoxaline 2,3-diones useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, seizure disorders, pain, Alzheimer's, Parkinson's, and Huntington's Diseases.
REFERENCES:
Copending U.S. application No. 08/443507, 1995.
C.F. Bigge, and T.C. Malone, "Agonists, Antagonists and Modulators of the N-methyl-D-aspartic acid (NMDA) and .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) Subtypes of Glutamate Receptors", Current Opinion in Therapeutic Patents, 1993, pp. 951-989.
M. Rogawski, "Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines", TiPS, vol. 14, 1993, pp. 325-331.
H. Li and A.M. Buchan, "Treatment with an AMPA Antagonists 12 Hours Following Severe Normothermic Forebrain Ischemia Prevents CA.sub.1 Neuronal Injury", Journal of Cerebral Blood Flow and Metabolism, vol. 13, No. 6, 1993, pp. 933-939.
B. Nellg.ang.rd and T. Wieloch, "Postischemic Blockade of AMPA but not NMDA Receptors Mitigates Neuronal Damage in the Rat Brain Following Transient Severe Cerebral Ischemia", Journal of Cerebral Blood Flow and Metabolism, vol. 12, No. 1, 1992, pp. 2-11.
R. Bullock et al., "Neuroprotective Effect of the AMPA Receptor Antagonist LY-293558 in Focal Cerebral Ischemia", Journal of Cerebral Blood Flow and Metabolism, vol. 14, No. 3, 1994, pp. 466-471.
D. Xue et al., "Delayed Treatment with AMPA, but Not NMDA, Antagonists Reduced Neocortical Infarction", Journal of Cerebral Blood Flow and Metabolism, vol. 14, No. 2, 1994, pp. 251-261.
X.-J. Xu et al., "Systemic Excitatory Amino Acid Receptor Antagonists of the .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropnionic acid (AMPA) Receptor and of the N-methyl-D-aspartate (NMDA) Receptor Relieve Mechanical Hypersensitivity After Transient Spinal Cord Ischemia in Rats", The Journal of Pharmacology and Experimental Therapeutics, vol. 267, No. 1, 1993, pp. 140-144.
T. Namba et al., "Antiepileptic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonists, in the rat kindling model of epilepsy", Brain Research, vol. 638, 1994, pp. 36-44.
S.E. Browne and J. McCulloch, "AMPA receptor antagonists and local cerebral glucose utilization in the rat", Brain Research, vol. 641, 1994, pp. 10-20.
S. Yamaguchi et al., "Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models", Epilepsy Research, vol. 15, 1993, pp. 179-184.
S. Smith et al., "The non-N-methyl-D-aspartate receptor antagonists, BYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy", European Journal of Pharmacology, vol. 201, 1991, pp. 179-183.
T. Klockgether et al., "The AMPA Receptor Antagonists NMQX Has Antiparkinsonian Effects in Monoamine-depleted Rats and MPTP-treated Monkeys", Annals of Neurology, vol. 30, No. 5, 1991, pp. 717-723.
T. Klockgether and L. Turski, "Toward an Understanding of the Role of Glutamate in Experimental Parkinsonism: Agonists-Sensitive Sites in the Basal Ganglia", Annals of Neurology, vol. 34, No. 4, 1993, pp. 585-593.
P. Francis et al., "Cortical Pyramidal Neurone Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic Perspectives", Journal of Neurochemistry, vol. 60, No. 5, 1993, pp. 1589-1604.
S. Lipton, "Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide", TINS, vol. 16, No. 12, 1993, pp. 527-532.
S. Lipton and P. Rosenberg, "Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders", Review Article in Mechanisms of Disease, F. Epstein, Editor, vol. 380, No. 9, 1993, pp. 613-622.
C. Bigge, "Structural Requirements for the Development of Potent N-methyl-D-aspartic Acid (NMDA) Receptor Antagonists", Biochemical Pharmacology, vol. 45, No. 8, 1993, pp. 1547-1561.
T. Honore and M. Nielsen, "Complex Structure of Quisqualae-Sensitive Glutamate Receptors in Rat Cortex", Neuroscience Letters, vol. 54, 1985, pp. 27-32.
E. London and J. Coyle, "Specific Binding of [.sup.3 H]Kainic Acid to Receptor Sites in Rat Brain", Molecular Pharmacology, vol. 15, 1979, pp. 492-505.
S. Jones et al., "Characterization of the Binding of Radioligands to the N-Methyl-D-Aspartate, Phencyclidine, and Glycine Receptors in Buffy Coat Membranes", Journal of Pharmacological Methods, vol. 21, 1989, pp. 161-168.
J.-Y. Koh et al., "Non-NMDA Receptor-Mediated Neurotoxicity in Cortical Culture", Journal of Neuroscience, vol. 10, No. 2, 1990, pp. 693-705.
R. Kall et al., "Antiepileptic Drug Development: II. Anticonvulsant Drug Screening", Epilepsia, vol. 19, 1978, pp. 409-428.
Abstract for JP 06228112 (Aug. 16, 1994), Yamanouchi Pharm.
Acklin et al, Chemical Abstracts, vol. 126, No. 251169 (Abstract for WO 9708155, Mar. 6, 1997) (1997).
Kornberg Brian Edward
Nikam Sham Shridhar
Anderson Elizabeth M.
Bernhardt Emily
Warner-Lambert & Company
LandOfFree
Sulfonamide derivatives of substituted quinoxaline 2,3-diones as does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonamide derivatives of substituted quinoxaline 2,3-diones as, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonamide derivatives of substituted quinoxaline 2,3-diones as will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-664183